CN101006074B - 作为nk1拮抗剂的哌啶衍生物 - Google Patents
作为nk1拮抗剂的哌啶衍生物 Download PDFInfo
- Publication number
- CN101006074B CN101006074B CN2005800285965A CN200580028596A CN101006074B CN 101006074 B CN101006074 B CN 101006074B CN 2005800285965 A CN2005800285965 A CN 2005800285965A CN 200580028596 A CN200580028596 A CN 200580028596A CN 101006074 B CN101006074 B CN 101006074B
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- etoac
- solution
- reaction mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC*([C@](C)C(CCC#ICC1)C[C@@]1(CO[C@](C)c1cc(**)cc(N)c1)C1=CC=CCC1)C=* Chemical compound CC*([C@](C)C(CCC#ICC1)C[C@@]1(CO[C@](C)c1cc(**)cc(N)c1)C1=CC=CCC1)C=* 0.000 description 13
- HAZRTOLOFMIXAN-UHFFFAOYSA-N CC(C(C=CC(N)=C1)C=C1N)OC#C Chemical compound CC(C(C=CC(N)=C1)C=C1N)OC#C HAZRTOLOFMIXAN-UHFFFAOYSA-N 0.000 description 1
- GRHLBELNWMNKNV-UHFFFAOYSA-N CC(C(CC(N)=C1)C=C1N)OC Chemical compound CC(C(CC(N)=C1)C=C1N)OC GRHLBELNWMNKNV-UHFFFAOYSA-N 0.000 description 1
- MSORHTUYZUILLB-UHFFFAOYSA-N CN[N]1(C)CNC1 Chemical compound CN[N]1(C)CNC1 MSORHTUYZUILLB-UHFFFAOYSA-N 0.000 description 1
- HZFTYVBQLOSMPM-MDJGFUSWSA-N C[C@H](C(CC(C1)C(F)(F)F)=CC1C(F)(F)F)OC[C@](CC1)(C2C=CC=CC2)NC/C1=N/C(C(C)(C)N)=O Chemical compound C[C@H](C(CC(C1)C(F)(F)F)=CC1C(F)(F)F)OC[C@](CC1)(C2C=CC=CC2)NC/C1=N/C(C(C)(C)N)=O HZFTYVBQLOSMPM-MDJGFUSWSA-N 0.000 description 1
- JEJHOJMIRDCHGO-SHVQYXQLSA-N C[C@H](c1cc(C(F)(F)F)cc(C(F)(F)F)c1)OCC(CC1)(c2ccccc2)NC[C@]1(CO)N(C=N)C=N Chemical compound C[C@H](c1cc(C(F)(F)F)cc(C(F)(F)F)c1)OCC(CC1)(c2ccccc2)NC[C@]1(CO)N(C=N)C=N JEJHOJMIRDCHGO-SHVQYXQLSA-N 0.000 description 1
- RGCLHLWTUYZCOA-URZJWIJPSA-N C[C@H](c1cc(C(F)(F)F)cc(C(F)(F)F)c1)OCC[C@](CC1)(c2ccccc2)N(C)C[C@H]1N Chemical compound C[C@H](c1cc(C(F)(F)F)cc(C(F)(F)F)c1)OCC[C@](CC1)(c2ccccc2)N(C)C[C@H]1N RGCLHLWTUYZCOA-URZJWIJPSA-N 0.000 description 1
- BTZKPNRGVSYVEW-PEIYMZMQSA-N C[C@H](c1cc(C(F)(F)F)cc(C(F)(F)F)c1)OC[C@](CC1)(c2ccccc2)NCC1[N+]1(C)[I-]C2(CC2)C1=O Chemical compound C[C@H](c1cc(C(F)(F)F)cc(C(F)(F)F)c1)OC[C@](CC1)(c2ccccc2)NCC1[N+]1(C)[I-]C2(CC2)C1=O BTZKPNRGVSYVEW-PEIYMZMQSA-N 0.000 description 1
- KQJOHHCXHAVVDT-UOKFIYJESA-N C[C@H](c1cc(C(F)(F)F)cc(C(F)(F)F)c1)OC[C@](CC1)(c2ccccc2)NC[C@@]1(C#N)N(CC1)C1=O Chemical compound C[C@H](c1cc(C(F)(F)F)cc(C(F)(F)F)c1)OC[C@](CC1)(c2ccccc2)NC[C@@]1(C#N)N(CC1)C1=O KQJOHHCXHAVVDT-UOKFIYJESA-N 0.000 description 1
- WYFPXPCVVDUIPG-UKDVSSAZSA-N C[C@H](c1cc(C(F)(F)F)cc(C(F)(F)F)c1)OC[C@](CC1)(c2ccccc2)NC[C@]1(C)N1C=[N]=C(C)C1 Chemical compound C[C@H](c1cc(C(F)(F)F)cc(C(F)(F)F)c1)OC[C@](CC1)(c2ccccc2)NC[C@]1(C)N1C=[N]=C(C)C1 WYFPXPCVVDUIPG-UKDVSSAZSA-N 0.000 description 1
- IZEGLXIHHZHHMD-JSGCOSHPSA-N O=C[C@](CC1)(CN[C@@H]1c1ccccc1)N(C=NN1)C1=O Chemical compound O=C[C@](CC1)(CN[C@@H]1c1ccccc1)N(C=NN1)C1=O IZEGLXIHHZHHMD-JSGCOSHPSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
Description
Claims (19)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58450204P | 2004-07-01 | 2004-07-01 | |
US60/584,502 | 2004-07-01 | ||
PCT/US2005/023427 WO2006007540A2 (en) | 2004-07-01 | 2005-06-29 | Piperidine derivatives as nk1 antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101006074A CN101006074A (zh) | 2007-07-25 |
CN101006074B true CN101006074B (zh) | 2012-02-15 |
Family
ID=35453353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800285965A Expired - Fee Related CN101006074B (zh) | 2004-07-01 | 2005-06-29 | 作为nk1拮抗剂的哌啶衍生物 |
Country Status (26)
Country | Link |
---|---|
US (6) | US7709641B2 (zh) |
EP (3) | EP3269713A1 (zh) |
JP (1) | JP2008505107A (zh) |
KR (1) | KR101228282B1 (zh) |
CN (1) | CN101006074B (zh) |
AR (2) | AR049655A1 (zh) |
AU (1) | AU2005262330B2 (zh) |
BR (1) | BRPI0512958A (zh) |
CA (1) | CA2570197C (zh) |
EC (1) | ECSP067123A (zh) |
ES (2) | ES2632413T3 (zh) |
HK (2) | HK1102962A1 (zh) |
HU (1) | HUE027791T2 (zh) |
IL (1) | IL180329A0 (zh) |
MX (1) | MX2007000030A (zh) |
MY (1) | MY142804A (zh) |
NO (1) | NO340368B1 (zh) |
NZ (1) | NZ552059A (zh) |
PE (1) | PE20060483A1 (zh) |
PL (1) | PL1799666T3 (zh) |
PT (1) | PT1799666E (zh) |
RU (1) | RU2408591C9 (zh) |
SG (2) | SG154443A1 (zh) |
TW (1) | TWI348467B (zh) |
WO (1) | WO2006007540A2 (zh) |
ZA (1) | ZA200610666B (zh) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20030762A1 (es) | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
MY142804A (en) | 2004-07-01 | 2011-01-14 | Opko Health Inc | Nk1 antagonists |
EP2004646B1 (en) * | 2006-04-05 | 2016-06-08 | OPKO Health, Inc. | Hydrochloride salt of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor |
CN103751186B (zh) | 2006-04-05 | 2016-08-24 | 欧科生医股份有限公司 | 药物制剂:8-[{1-(3,5-双-(三氟甲基)苯基)-乙氧基}-甲基]-8-苯基-1,7-二氮杂-螺[4.5]癸-2-酮的盐及用其治疗的方法 |
AR066191A1 (es) * | 2007-03-22 | 2009-08-05 | Schering Corp | Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona |
WO2009000038A1 (en) * | 2007-06-28 | 2008-12-31 | Cnsbio Pty Ltd | Combination methods and compositions for treatment of neuropathic pain |
US8138168B1 (en) | 2007-09-26 | 2012-03-20 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
KR101719004B1 (ko) | 2008-09-05 | 2017-03-22 | 옵코 헬스, 인크. | 8-[{1-(3,5-비스-(트리플루오로메틸)페닐)-에톡시}-메틸]-8-페닐-1,7-디아자-스피로[4.5]데칸-2-온 화합물의 합성 방법 및 중간체 |
EP3143996A1 (en) * | 2009-08-14 | 2017-03-22 | OPKO Health, Inc. | Intravenous formulations of neurokinin 1-antagonists |
JP2013510145A (ja) * | 2009-11-09 | 2013-03-21 | メディヴィル・アクチエボラーグ | 1,3−オキサゾリジン化合物およびレニン阻害剤としてのそれらの使用方法 |
AU2011254656B2 (en) | 2010-05-19 | 2015-04-16 | Sandoz Ag | Process for the preparation of chiral hydrazides |
EP2571868B1 (en) | 2010-05-19 | 2016-05-04 | Sandoz AG | Preparation of posaconazole intermediates |
MX342850B (es) | 2010-05-19 | 2016-10-14 | Sandoz Ag | Proceso para la preparacion de triazolonas quirales. |
BR112012029228A2 (pt) | 2010-05-19 | 2021-08-03 | Sandoz Ag | processo para a preparação de um sal de cloreto de hidrogênio, sal de cloreto de hidrogênio, sal de cloreto de hidrogênio cristalino, uso de um sal e uso do processo |
CN103635465A (zh) | 2011-06-16 | 2014-03-12 | 桑多斯股份公司 | 制备手性化合物的方法 |
US9358228B2 (en) * | 2011-10-18 | 2016-06-07 | Helsinn Healthcare Sa | Therapeutic combinations of netupitant and palonosetron |
CA2991898A1 (en) * | 2015-07-15 | 2017-01-19 | Opko Health, Inc. | Heteroaryl carbonitriles for the treatment of disease |
CN108148060B (zh) * | 2016-12-05 | 2020-06-19 | 四川科伦博泰生物医药股份有限公司 | 取代的杂环化合物及其衍生物,其药物组合物、制备方法及用途 |
WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
WO2020048828A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds |
CN114958325B (zh) * | 2021-02-24 | 2023-06-27 | 中国石油化工股份有限公司 | 一种耐高温缓蚀剂、制备方法及其在井筒防腐中的应用 |
WO2024084363A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Use of patatin-like phospholipase domain-containing protein 3 compounds |
WO2024084360A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1095591A (zh) * | 1992-12-23 | 1994-11-30 | 先灵公司 | 一种胆固醇生物合成抑制剂与一种β-内酰胺胆固醇吸收抑制剂的联合 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE188472T1 (de) | 1992-10-28 | 2000-01-15 | Merck Sharp & Dohme | 4-arylmethyloxymethyl piperidine als tachykinin antagonisten |
JPH08504435A (ja) * | 1992-12-14 | 1996-05-14 | メルク シヤープ エンド ドーム リミテツド | タキキニン受容体拮抗剤としての4−アミノメチル/チオメチル/スルホニルメチル−4−フェニルピペリジン |
AU685212B2 (en) | 1994-01-13 | 1998-01-15 | Merck Sharp & Dohme Limited | Gem-disubstituted azacyclic tachykinin antagonists |
DE69728883T2 (de) | 1996-07-17 | 2005-04-07 | Merck & Co., Inc. | Änderung des zirkadischen rhythmus mit nicht-peptidischen neurokinin-1 rezeptor antagonisten |
US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
JP2001523245A (ja) | 1997-04-24 | 2001-11-20 | メルク シヤープ エンド ドーム リミテツド | 肥満を治療するためのnk−1受容体拮抗薬およびssriの使用 |
US6436928B1 (en) | 1999-12-17 | 2002-08-20 | Schering Corporation | Selective neurokinin antagonists |
EP1451153B1 (en) * | 2001-11-13 | 2007-09-26 | Schering Corporation | Nk1 antagonists |
PE20030762A1 (es) * | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
MY142804A (en) | 2004-07-01 | 2011-01-14 | Opko Health Inc | Nk1 antagonists |
-
2005
- 2005-06-29 MY MYPI20052967A patent/MY142804A/en unknown
- 2005-06-29 CN CN2005800285965A patent/CN101006074B/zh not_active Expired - Fee Related
- 2005-06-29 SG SG200904485-0A patent/SG154443A1/en unknown
- 2005-06-29 KR KR1020067027877A patent/KR101228282B1/ko active IP Right Grant
- 2005-06-29 AU AU2005262330A patent/AU2005262330B2/en not_active Ceased
- 2005-06-29 EP EP17165369.4A patent/EP3269713A1/en not_active Withdrawn
- 2005-06-29 JP JP2007519458A patent/JP2008505107A/ja active Pending
- 2005-06-29 MX MX2007000030A patent/MX2007000030A/es active IP Right Grant
- 2005-06-29 ES ES12169655.3T patent/ES2632413T3/es active Active
- 2005-06-29 BR BRPI0512958-3A patent/BRPI0512958A/pt not_active Application Discontinuation
- 2005-06-29 SG SG2012096624A patent/SG187416A1/en unknown
- 2005-06-29 AR ARP050102686A patent/AR049655A1/es not_active Application Discontinuation
- 2005-06-29 WO PCT/US2005/023427 patent/WO2006007540A2/en active Application Filing
- 2005-06-29 PT PT05787862T patent/PT1799666E/pt unknown
- 2005-06-29 HU HUE05787862A patent/HUE027791T2/en unknown
- 2005-06-29 RU RU2007103611/04A patent/RU2408591C9/ru not_active IP Right Cessation
- 2005-06-29 PL PL05787862.1T patent/PL1799666T3/pl unknown
- 2005-06-29 ES ES05787862.1T patent/ES2576555T3/es active Active
- 2005-06-29 EP EP12169655.3A patent/EP2522664B1/en active Active
- 2005-06-29 EP EP05787862.1A patent/EP1799666B1/en active Active
- 2005-06-29 CA CA2570197A patent/CA2570197C/en not_active Expired - Fee Related
- 2005-06-29 NZ NZ552059A patent/NZ552059A/en not_active IP Right Cessation
- 2005-06-30 PE PE2005000764A patent/PE20060483A1/es active IP Right Grant
- 2005-06-30 TW TW094122193A patent/TWI348467B/zh not_active IP Right Cessation
- 2005-06-30 US US11/172,289 patent/US7709641B2/en active Active
-
2006
- 2006-12-18 ZA ZA200610666A patent/ZA200610666B/xx unknown
- 2006-12-25 IL IL180329A patent/IL180329A0/en not_active IP Right Cessation
- 2006-12-27 EC EC2006007123A patent/ECSP067123A/es unknown
-
2007
- 2007-01-31 NO NO20070588A patent/NO340368B1/no not_active IP Right Cessation
- 2007-07-11 HK HK07107432.4A patent/HK1102962A1/zh not_active IP Right Cessation
-
2010
- 2010-03-30 US US12/750,420 patent/US8026364B2/en active Active
-
2011
- 2011-09-26 US US13/245,403 patent/US8754216B2/en active Active
-
2014
- 2014-06-13 US US14/304,163 patent/US9469629B2/en active Active
-
2016
- 2016-02-29 AR ARP160100524A patent/AR103812A2/es unknown
- 2016-10-14 US US15/293,962 patent/US9969711B2/en active Active
-
2018
- 2018-03-28 US US15/938,409 patent/US20180215729A1/en not_active Abandoned
- 2018-05-28 HK HK18106977.4A patent/HK1247610A1/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1095591A (zh) * | 1992-12-23 | 1994-11-30 | 先灵公司 | 一种胆固醇生物合成抑制剂与一种β-内酰胺胆固醇吸收抑制剂的联合 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101006074B (zh) | 作为nk1拮抗剂的哌啶衍生物 | |
DE60316841T2 (de) | Triazolderivate als inhibitoren von 11-beta-hydroxysteroid-dehydrogenase-1 | |
JP4592077B2 (ja) | 嘔吐、抑鬱、不安および咳の処置のためのニューロキニン−1(nk−1)アンタゴニストとしての1−アミド−4−フェニル−4−ベンジルオキシメチル−ピペリジン誘導体および関連化合物 | |
NL1028948C2 (nl) | Ortho gesubstitueerde aryl- of heteroarylamideverbindingen. | |
UA65536C2 (en) | Substituted indazole derivatives, a pharmaceutical composition for the inhibition of phosphodiesterase type iv or the production of tumor necrosis factor, intermediate compounds | |
DE60004504T2 (de) | Tetrahydropyranderivate und deren verwendung als therapeutische mittel | |
WO2006100009A1 (de) | Cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel | |
CN101903384A (zh) | 作为蛋白激酶Cθ抑制剂的[1H-吡唑并[3,4-B]吡啶-4-基]-苯基或-吡啶-2-基衍生物 | |
CN104125956B (zh) | 作为11-β-羟基类固醇脱氢酶的抑制剂的环酰胺及其用途 | |
JP2016505512A (ja) | Pde4のヘテロアリール阻害剤 | |
TW201625601A (zh) | 噻吩-2-基-吡啶-2-基-1h-吡唑-4-羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 | |
KR20040065289A (ko) | Nk1 길항제로서 피롤리딘 및 피페리딘 유도체 | |
CN101115753A (zh) | 桥环nk1拮抗剂 | |
EP1931647A2 (de) | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel | |
CA2570046A1 (en) | Substituted triazole derivatives as oxytocin antagonists | |
CN110461838B (zh) | 噁二唑瞬时受体电位通道抑制剂 | |
WO2007045672A1 (de) | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel | |
WO2001032633A1 (de) | Substituierte 5-benzyl-2,4-diaminopyrimidine | |
WO2007057775A1 (en) | Spiropiperidine derivatives | |
CN108473470A (zh) | 作为可溶性鸟苷酸环化酶激活剂的茚满衍生物及其用途 | |
JP4174068B1 (ja) | アンドロゲンモジュレーター | |
WO2007036533A2 (de) | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel | |
JP2010526051A (ja) | 疼痛を治療するためのnav1.8チャネルモジュレーターとしてのn−[6−アミノ−5−(フェニル)ピラジン−2−イル]−イソオキサゾール−4−カルボキサミド誘導体および関連化合物 | |
JP2008543826A (ja) | ORL1−受容体アンタゴニストとしてのα−(アリール−またはヘテロアリール−メチル)−β−ピペリジノプロパン酸化合物 | |
EP1753718A1 (en) | 3-amino-2-phenylpyrrolidine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: OKSING MEDICAL CO., LTD. Free format text: FORMER OWNER: SCHERING CO., LTD. Effective date: 20100420 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: NEW JERSEY, U.S.A. TO: FLORIDA STATE, U.S.A |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20100420 Address after: American Florida Applicant after: Schering Corp. Address before: new jersey Applicant before: SCHERING CORP (US) |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120215 Termination date: 20190629 |